June 07, 2023
The device, used with certain chemotherapies and immunotherapies, helps in creating electric fields that disrupt cancer cell growth. However, only a small group of patients enrolled in the study were previously treated with ICI such as Merck's Keytruda in first line setting, while a majority of the patients were given the ICI as second-line treatment in the study.
Some analysts also said that the device may not do well commercially at least in the United States, where checkpoint inhibitors are currently the standard of care.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: